Medplus Health Q1 FY27 Revenue at ₹18,796m, Up 21.8% YoY
Medplus Health reported Q1 FY27 revenue of ₹18,796 million, up 21.8% YoY. Gross margin was ₹4,603 million (24.5% GM%). The company added 146 net stores, reaching a total of 5,476. Pharmacy Operating EBITDA was ₹588 million, and Company Operating EBITDA was ₹651 million. Operating Cash Flow was ₹1,252 million.
The results show strong top-line growth and expansion, but a decrease in gross margin percentage and pharmacy operating EBITDA margin suggests some pressure on profitability, warranting a medium impact assessment.
The company reported significant year-on-year revenue growth and an increase in store count, indicating positive business momentum.
MedPlus Health Services Limited announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a revenue of ₹18,796 million, marking a significant 21.8% year-on-year increase from ₹15,426 million in Q1 FY26. Revenue also saw a 0.8% quarter-on-quarter growth from ₹18,644 million in Q4 FY26.
Gross Margin for the quarter stood at ₹4,603 million, with a Gross Margin percentage of 24.5%. This represents a decrease of 160 basis points year-on-year and 200 basis points quarter-on-quarter.
The company added 146 stores during the quarter, bringing the total store count to 5,476 as of June 30, 2026. Stores older than 12 months demonstrated strong performance with 15.3% revenue growth year-on-year, a 10.4% store-level EBITDA margin, and a 63.0% store-level operating ROCE.
Pharmacy Operating EBITDA was reported at ₹588 million, with an operating EBITDA margin of 3.2% in the pharmacy segment. Company Operating EBITDA was ₹651 million. Operating Cash Flow was ₹1,252 million, representing 192.2% of Operating EBITDA, and the company maintained a closing cash and bank balance of ₹6,219 million.
The investor presentation also detailed the company's strategy focusing on growth in existing clusters, leveraging its omni-channel leadership, and expanding the share of private label products. The company highlighted its strong cluster-based network enabling profitable omni-channel service and its scale allowing for a large private label basket of over 1550 SKUs.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.